

Prophylactic granulocyte-macrophage colony-stimulating factor (GM-CSF) to reduce sepsis in preterm neonates

Submission date 01/03/2001	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/03/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 30/04/2015	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Neena Modi

Contact details
Senior Lecturer/Consultant in Neonatal Paediatrics
Department of Paediatrics
Hammersmith Hospital
Du Cane Road
London
United Kingdom
W12 0NN
+44 (0)20 8383 3275
n.modi@ic.ac.uk

Additional identifiers

Protocol serial number
SP3558

Study information

Scientific Title

Prophylactic granulocyte-macrophage colony-stimulating factor (GM-CSF) to reduce sepsis in preterm neonates: a randomised controlled trial

Acronym

PROGRAMS

Study objectives

To estimate the economic efficiency of administering prophylactic granulocytic-macrophage colony stimulating factor to preterm neonates at high risk of sepsis.

Please note that as of 21/01/2009 this record was updated. All update details can be found under the relevant field with the above update date.

Ethics approval required

Old ethics approval format

Ethics approval(s)

NHS Executive South East MREC, 27/01/2000, ref: 99/85

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Sepsis

Interventions

1. Once daily granulocyte-macrophage colony-stimulating factor (GM-CSF) 10 µg/kg by subcutaneous injection, commenced within 72 hours of birth and continued for 5 days
2. No GM-CSF therapy

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Granulocyte-macrophage colony-stimulating factor (GM-CSF)

Primary outcome(s)

1. Sepsis-free survival at 14 days from trial entry
2. Economic evaluation outcome: incremental cost-effectiveness analysis

Key secondary outcome(s)

Added 21/01/2009:

1. Survival without moderate/severe disability at 2 years from term
2. Survival to discharge
3. Sepsis:
 - 3.1. Culture positive systemic infection, to 14 days from trial entry
 - 3.2. Culture negative systemic infection, to 14 days from trial entry
 - 3.3. Probable (culture positive or negative) systemic infection, to 28 days from trial entry
4. Clinical morbidity:
 - 4.1. Chronic lung disease (bronchopulmonary dysplasia)
 - 4.2. Necrotising enterocolitis, periventricular haemorrhage
 - 4.3. Periventricular leucomalacia and ventriculomegaly
5. Haematological:
 - 5.1. Culture positive systemic infection associated with neutropenia, to 14 days from trial entry
 - 5.2. Culture positive systemic infection associated with neutropenia, to 28 days from trial entry

Completion date

01/09/2005

Eligibility

Key inclusion criteria

Babies are eligible for PROGRAMS if they are less than or equal to 31 completed weeks gestational age and small for gestational age (i.e. below 10th centile for birthweight) and within 72 hours of birth.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Neonate

Sex

All

Key exclusion criteria

Added 21/01/2009:

1. Immediately life-threatening congenital abnormality
2. Evidence of early onset sepsis (maternal pyrexia greater than 38.0°C on two consecutive occasions during labour)

Date of first enrolment

01/09/2001

Date of final enrolment

01/09/2005

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Hammersmith Hospital

London

United Kingdom

W12 0NN

Sponsor information

Organisation

Imperial College London (UK)

ROR

<https://ror.org/041kmwe10>

Funder(s)

Funder type

Charity

Funder Name

Action Medical Research (UK)

Alternative Name(s)

action medical research for children, actionmedres, The National Fund for Research into Crippling Diseases, AMR

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

The Wellcome Trust (UK) (added 05/01/2010) (grant ref: 068499)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/01/2009		Yes	No
Results article	results	01/07/2015		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes